{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:52:20Z","timestamp":1767840740578,"version":"3.49.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/md.0000000000003310","type":"journal-article","created":{"date-parts":[[2016,5,2]],"date-time":"2016-05-02T18:33:10Z","timestamp":1462213990000},"page":"e3310","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia"],"prefix":"10.1097","volume":"95","author":[{"given":"Xiangyun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongni","family":"Zu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongwu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-36-20210309","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","article-title":"Hyponatremia","volume":"342","author":"Adrogu\u00e9","year":"2000","journal-title":"N Engl J Med"},{"key":"R2-36-20210309","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.semnephrol.2009.03.004","article-title":"Epidemiology of hyponatremia","volume":"29","author":"Upadhyay","year":"2009","journal-title":"Semin Nephrol"},{"key":"R3-36-20210309","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1097\/CCM.0b013e3181dda0be","article-title":"Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit","volume":"38","author":"Buckley","year":"2010","journal-title":"Crit Care Med"},{"key":"R4-36-20210309","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198810203191606","article-title":"Pathogenesis of sodium and water in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis and pregnancy","volume":"319","author":"Schrier","year":"1988","journal-title":"N Engl J Med"},{"key":"R5-36-20210309","doi-asserted-by":"crossref","first-page":"c62","DOI":"10.1159\/000324653","article-title":"The syndrome of inappropriate antidiuresis: pathophysiology, clinical management and new therapeutic options","volume":"119","author":"Esposito","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"R6-36-20210309","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-13-1020","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"170","author":"Spasovski","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"R7-36-20210309","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/0003-4819-78-6-870","article-title":"Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone: an alternative treatment to hypertonic saline","volume":"78","author":"Hantman","year":"1973","journal-title":"Ann Intern Med"},{"key":"R8-36-20210309","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1001\/jama.1980.03300500039026","article-title":"Plasma demeclocycline concentrations and nephrotoxicity: correlation in hyponatremic cirrhotic patients","volume":"243","author":"Miller","year":"1980","journal-title":"JAMA"},{"key":"R9-36-20210309","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrendo.2010.229","article-title":"Vaptans for the treatment of hyponatremia","volume":"7","author":"Robertson","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"R10-36-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R11-36-20210309","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in Meta analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"R12-36-20210309","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"R13-36-20210309","doi-asserted-by":"crossref","first-page":"b4012","DOI":"10.1136\/bmj.b4012","article-title":"Risk of bias versus quality assessment of randomised controlled trials: cross sectional study","volume":"339","author":"Hartling","year":"2009","journal-title":"BMJ"},{"key":"R14-36-20210309","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R15-36-20210309","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R16-36-20210309","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/jc.2005-2287","article-title":"Efficacy and safety of oral conivaptan: a V1A\/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"91","author":"Ghali","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-36-20210309","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MAJ.0b013e31817b8148","article-title":"Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemicor hypervolemic hyponatremia","volume":"337","author":"Annane","year":"2009","journal-title":"Am J Med Sci"},{"key":"R18-36-20210309","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2265.2007.03149.x","article-title":"Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study","volume":"69","author":"Verbalis","year":"2008","journal-title":"Clin Endocrinol (Oxf"},{"key":"R19-36-20210309","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2146\/ajhp100260","article-title":"Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia","volume":"68","author":"Koren","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"R20-36-20210309","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000106456","article-title":"Assessmentof the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia","volume":"27","author":"Zeltser","year":"2007","journal-title":"Am J Nephrol"},{"key":"R21-36-20210309","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2003.50021","article-title":"A vasopressin receptor antagonist (VPA-985) improve serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial","volume":"37","author":"Wong","year":"2003","journal-title":"Hepatology"},{"key":"R22-36-20210309","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/gast.2003.50143","article-title":"Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial","volume":"124","author":"Gerbes","year":"2003","journal-title":"Gastroenterology"},{"key":"R23-36-20210309","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/ki.2012.274","article-title":"Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia","volume":"82","author":"Abraham","year":"2012","journal-title":"Kidney Int"},{"key":"R24-36-20210309","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ki.2012.275","article-title":"Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia","volume":"82","author":"Abraham","year":"2012","journal-title":"Kidney Int"},{"key":"R25-36-20210309","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/eurjhf\/hfq226","article-title":"Short-and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study","volume":"13","author":"Aronson","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"R26-36-20210309","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2215\/CJN.00160106","article-title":"Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist","volume":"1","author":"Soupart","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R27-36-20210309","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1365-2036.2010.04236.x","article-title":"Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia-a randomized, double-blind, placebo-controlled study","volume":"31","author":"Gin\u00e8s","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-36-20210309","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jcph.342","article-title":"Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH","volume":"54","author":"Chen","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R29-36-20210309","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"R30-36-20210309","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","article-title":"Vasopressin v (2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia","volume":"97","author":"Gheorghiade","year":"2006","journal-title":"Am J Cardiol"},{"key":"R31-36-20210309","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jhep.2011.08.020","article-title":"Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis","volume":"56","author":"C\u00e1rdenas","year":"2012","journal-title":"J Hepatol"},{"key":"R32-36-20210309","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-10-1078","article-title":"Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion","volume":"164","author":"Verbalis","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"R33-36-20210309","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/cncr.28468","article-title":"Tolvaptan in hospitalized cancer patients with hyponatremia: a double blind, randomized, placebo-controlled clinical trial on efficacy and safety","volume":"120","author":"Salahudeen","year":"2014","journal-title":"Cancer"},{"key":"R34-36-20210309","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in Meta analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"R35-36-20210309","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJM198504253121709","article-title":"Treatment of hyponatremia","volume":"312","author":"Schrier","year":"1985","journal-title":"N Engl J Med"},{"key":"R36-36-20210309","first-page":"F3","article-title":"Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin","volume":"272","author":"Knepper","year":"1997","journal-title":"Am J Physiol"},{"key":"R37-36-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0290001","article-title":"Vasopressin V2 receptor antagonists","volume":"29","author":"Verbalis","year":"2002","journal-title":"J Mol Endocrinol"},{"key":"R38-36-20210309","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.amjmed.2011.04.028","article-title":"Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia","volume":"124","author":"Jaber","year":"2011","journal-title":"Am J Med"},{"key":"R39-36-20210309","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.ajkd.2010.01.013","article-title":"Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis","volume":"56","author":"Rozen-Zvi","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R40-36-20210309","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/ndt\/gfm136","article-title":"V2-antagonists for the treatment of hyponatraemia","volume":"22","author":"Decaux","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R41-36-20210309","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1056\/NEJMoa042743","article-title":"Nephrogenic syndrome of inappropriate antidiuresis","volume":"352","author":"Feldman","year":"2005","journal-title":"N Engl J Med"},{"key":"R42-36-20210309","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1681\/ASN.2006090987","article-title":"Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree","volume":"18","author":"Decaux","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R43-36-20210309","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjmed.2013.07.006","article-title":"Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations","volume":"126","author":"Verbalis","year":"2013","journal-title":"Am J Med"},{"key":"R44-36-20210309","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2009080857","article-title":"Oral tolvaptan is safe and effective in chronic hyponatremia","volume":"21","author":"Berl","year":"2010","journal-title":"J Am Soc Nephrol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000003310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T05:03:48Z","timestamp":1718514228000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201604120-00036"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":44,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000003310","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}